Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma-Reference-Cited by-同舟云学术

Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma

Published:2024-05 Issue: Volume:202 Page:113976
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Albrecht Lea Jessica,Dimitriou Florentia,Grover Piyush,Hassel Jessica C.,Erdmann Michael,Forschner Andrea,Johnson Douglas B.,Váraljai Renáta,Lodde Georg,Placke Jan Malte,Krefting Frederik,Zaremba Anne,Ugurel Selma,Roesch Alexander,Schulz Carsten,Berking Carola,Pöttgen Christoph,Menzies Alexander M.,Long Georgina V.,Dummer Reinhard,Livingstone Elisabeth,Schadendorf Dirk,Zimmer Lisa

Publisher

Elsevier BV

Reference30 articles.

1. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma;Robert;N Engl J Med,2019

2. Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma;Wolchok;J Clin Oncol,2022

3. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study;Robert;Lancet Oncol,2019

4. Nivolumab in previously untreated melanoma without BRAF mutation;Robert;N Engl J Med,2015

5. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma;Larkin;N Engl J Med,2019

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunotherapy revolutionizing buccal carcinoma treatment: Harnessing immune checkpoint inhibitors to overcome immune evasion mechanisms;Oral Oncology Reports;2024-06

2. Agnostic Administration of Targeted Anticancer Drugs: Looking for a Balance between Hype and Caution;International Journal of Molecular Sciences;2024-04-07